From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

lepunafusp alfa   Click here for help

GtoPdb Ligand ID: 11773

Synonyms: JR-171 | JR171
Compound class: Antibody
Comment: Lepunafusp alfa (JR-171) is a blood-brain-barrier-penetrating form of recombinant human alpha-L-iduronidase (IDUA; P35475), an enzyme that is deficient in patients with the lysosomal storage disease mucopolysaccharidosis type I (MPS I; Hurler syndrome; Scheie syndrome) which leads to disrupted glycosaminoglycan catabolism [1-2]. The enzyme is fused to the same anti-transferrin receptor antibody Fab as pabinafusp alfa, to facilitate movement of the enzyme across the blood-brain barrier. Both lepunafusp and pabinafusp were developed using JCR Pharmaceuticals' proprietary J-Brain Cargo® technology [3].
No information available.
Summary of Clinical Use Click here for help
Lepunafusp alfa (JR-171) is being assessed for safety and efficacy in MPS I patients. It was granted EMA orphan drug designation as a treatment for MPS I in March 2021.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04227600 A Study of JR-171 in Patients With Mucopolysaccharidosis I Phase 1/Phase 2 Interventional JCR Pharmaceuticals Co., Ltd.
NCT04453085 An Extension Study of JR-171-101 Study in Patients With MPS I Phase 1/Phase 2 Interventional JCR Pharmaceuticals Co., Ltd.